Endocrine Therapy in combination with Anti-VEGF (vascular endothelial growth factor) therapy: A randomized, double-blind, placebo controlled Phase III Trial of endocrine (hormone) therapy alone or endocrine therapy plus bevacizumab (Avastin) for women with hormone receptor-positive advanced breast cancer
This trial is being done to compare disease progression free survival of letrozole or tamoxifen therapy plus placebo with the combination of letrozole (Femara) or tamoxifen plus bevacizumab (Avastin) as first line treatment in women with estrogen and/or progesterone receptor positive advanced breast cancer. Avastin works by interfering with the process of angiogenesis (growth of new blood vessels) by targeting and inhibiting human vascular endothelial growth factor (VEGF).
Patients on hormonal therapy will be randomized to receive bevacizumab or placebo. Bevacizumab/placebo and Letrozole provided at no charge.
Basic Eligibility Criteria:
If you would like information about enrolling into a clinical trial at El Camino Hospital, please contact:
Clinical Research Coordinator
Fogarty Clinical Research